ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Follicular Lymphoma

Non-Hodgkin Lymphoma trials near Nashville, TN, USA:

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393

Phase 1

Arvinas
Arvinas

Nashville, Tennessee, United States and 14 other locations

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Nashville, Tennessee, United States and 75 other locations

at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cem...

Enrolling
Lymphoma, Non-Hodgkin's
Multiple Myeloma
Drug: Dexamethasone Oral
Drug: cemsidomide

Phase 1, Phase 2

C4 Therapeutics

Nashville, Tennessee, United States and 12 other locations

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Nashville, Tennessee, United States and 35 other locations

A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin...

Active, not recruiting
Diffuse Large B Cell Lymphoma (DLBCL)
Biological: bbT369

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Nashville, Tennessee, United States and 3 other locations

of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing)....

Enrolling
Hodgkin Lymphoma, Adult
Hodgkin Lymphoma
Drug: MT-601

Phase 1

Marker Therapeutics

Nashville, Tennessee, United States and 6 other locations

This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non...

Active, not recruiting
Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Extranodal NK/T-cell Lymphoma
Drug: CD30.CAR-T

Phase 1

Tessa Therapeutics

Nashville, Tennessee, United States and 3 other locations

lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).As of October 2022, no furt...

Active, not recruiting
Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Drug: Cyclophosphamide
Biological: Brexucabtagene Autoleucel (KTE-X19)

Phase 1, Phase 2

Gilead Sciences
Gilead Sciences

Nashville, Tennessee, United States and 29 other locations

if it works to treat the diseases under study. The diseases under study will be Renal Cell Carcinoma (RCC),Nasopharyngeal Carcinoma (NPC) and Non...

Enrolling
Non Hodgkin Lymphoma
Nasopharyngeal Carcinoma
Drug: PRO1160

Phase 1, Phase 2

ProfoundBio

Nashville, Tennessee, United States and 17 other locations

The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigati...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Dexamethasone
Drug: CC-122

Phase 1

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Nashville, Tennessee, United States and 6 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems